Insmed (INSM) Stock Price, News & Analysis

Company Overview

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Key Stats

• Today's Range: $96.39 to $100.00
• 50-Day Range: $64.81 to $97.98
• 52-Week Range: $60.40 to $100.00
• Volume: 7.17 million shs
• Average Volume: 2.16 million shs
• Market Capitalization: $17.65 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $104.81
• Consensus Rating: Buy

Insmed Stock Analysis - MarketRank™

Insmed scored higher than 67% of companies evaluated by MarketBeat, and ranked 339th out of 942 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Buy

Consensus Rating

Insmed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 18 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Insmed has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Insmed are expected to grow in the coming year, from ($4.56) to ($2.89) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Insmed is -17.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Insmed is -17.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.23% of the float of Insmed has been sold short.

Short Interest Ratio / Days to Cover

Insmed has a short interest ratio ("days to cover") of 7.

Change versus previous month

Short interest in Insmed has recently increased by 6.01%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Insmed does not currently pay a dividend.

Dividend Growth

Insmed does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -1.58

Percentage of Shares Shorted

10.23% of the float of Insmed has been sold short.

Short Interest Ratio / Days to Cover

Insmed has a short interest ratio ("days to cover") of 7.

Change versus previous month

Short interest in Insmed has recently increased by 6.01%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.87

News Sentiment

Insmed has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 62 news articles for Insmed this week, compared to 12 articles on an average week.

Search Interest

15 people have searched for INSM on MarketBeat in the last 30 days. This is an increase of 114% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Insmed to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Insmed insiders have sold 10,106.35% more of their company's stock than they have bought. Specifically, they have bought $201,694.00 in company stock and sold $20,585,587.00 in company stock.

Percentage Held by Insiders

Only 3.00% of the stock of Insmed is held by insiders.

INSM Stock Analysis - Frequently Asked Questions

How have INSM shares performed this year?

Insmed's stock was trading at $69.04 on January 1st, 2025. Since then, INSM shares have increased by 40.3% and is now trading at $96.88.
View the best growth stocks for 2025 here.

How were Insmed's earnings last quarter?

Insmed Incorporated (NASDAQ:INSM) released its earnings results on Thursday, May, 8th. The biopharmaceutical company reported ($1.42) EPS for the quarter, missing analysts' consensus estimates of ($1.36) by $0.06. The firm's revenue was up 22.9% compared to the same quarter last year.
Read the conference call transcript.

Who are Insmed's major shareholders?

Insmed's top institutional investors include Vanguard Group Inc. (10.05%), Price T Rowe Associates Inc. MD (7.11%), Adage Capital Partners GP L.L.C. (1.90%) and Alliancebernstein L.P. (1.33%). Insiders that own company stock include William Lewis, Melvin Md Sharoky, Roger Adsett, John Drayton Wise, Sara Bonstein, David W J Mcgirr, Orlov S Nicole Schaeffer, Martina MD Flammer, Michael Alexander Smith, Clarissa Desjardins and Clarissa Desjardins.
View institutional ownership trends.

How do I buy shares of Insmed?

Shares of INSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Insmed own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Insmed investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), CrowdStrike (CRWD), Advanced Micro Devices (AMD) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 6/12/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:INSM
• CIK: 1104506
• Web: www.insmed.com
• Phone: 908-977-9900
• Fax: 732-438-0381
• Employees: 373
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $104.81
• High Stock Price Target: $120.00
• Low Stock Price Target: $75.00
• Potential Upside/Downside: +8.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 18 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($5.95)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$749.57 million
• Net Margins: -251.24%
• Pretax Margin: -251.01%
• Return on Equity: -4,773.73%
• Return on Assets: -54.58%

Debt

• Debt-to-Equity Ratio: 2.03
• Current Ratio: 6.37
• Quick Ratio: 5.99

Sales & Book Value

• Annual Sales: $381.03 million
• Price / Sales: 46.31
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.32) per share
• Price / Book: -41.76

Miscellaneous

• Outstanding Shares: 182,139,000
• Free Float: 170,673,000
• Market Cap: $17.65 billion
• Optionable: Optionable
• Beta: 0.80